Laboratory-reflex cryptococcal antigen screening is associated with a survival benefit in Tanzania

dc.contributor.authorFaini, D
dc.contributor.authorKalinjuma, A. V,
dc.contributor.authorKatende, A
dc.contributor.authorMbwaji, G
dc.contributor.authorMnzava, D
dc.contributor.authorNyuri, A
dc.contributor.author. Glass, T.R
dc.contributor.authorFurrer, H
dc.date.accessioned2021-11-09T10:44:57Z
dc.date.available2021-11-09T10:44:57Z
dc.date.issued2019
dc.description.abstractBackground: Cryptococcal antigen (CrAg) screening in persons with advanced HIV/AIDS is recommended to prevent death. Implementing CrAg screening only in outpatients may underestimate the true CrAg prevalence and decrease its potential impact. Our previous 12-month survival/retention in CrAg-positive persons not treated with fluconazole was 0%. Methods: HIV testing was offered to all antiretroviral therapy– naive outpatients and hospitalized patients in Ifakara, Tanzania, followed by laboratory-reflex CrAg screening for CD4 ,150 cells/ mL. CrAg-positive individuals were offered lumbar punctures, and antifungals were tailored to the presence/absence of meningitis. We assessed the impact on survival and retention-in-care using multivariate Cox-regression models. Results: We screened 560 individuals for CrAg. The median CD4 count was 61 cells/mL (interquartile range 26–103). CrAg prevalence was 6.1% (34/560) among individuals with CD4 #150 and 7.5% among #100 cells/mL. CrAg prevalence was 2.3-fold higher among hospitalized participants than in outpatients (12% vs 5.3%, P = 0.02). We performed lumbar punctures in 94% (32/34), and 31% (10/34) had cryptococcal meningitis. Mortality did not differ significantly between treated CrAg-positive without meningitis and CrAg-negative individuals (7.3 vs 5.4 deaths per 100 person-years, respectively, P = 0.25). Independent predictors of 6-month death/lost to follow-up were low CD4, cryptococcal meningitis (adjusted hazard ratio 2.76, 95% confidence interval: 1.31 to 5.82), and no antiretroviral therapy initiation (adjusted hazard ratio 3.12, 95% confidence interval: 2.16 to 4.50). Conclusions: Implementing laboratory-reflex CrAg screening among outpatients and hospitalized individuals resulted in a rapid detection of cryptococcosis and a survival benefit. These results provide a model of a feasible, effective, and scalable CrAg screening and treatment strategy integrated into routine care in sub-Saharan Africa.en_US
dc.identifier.urihttp://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/2719
dc.language.isoenen_US
dc.publisherCLINICAL SCIENCEen_US
dc.relation.ispartofseriesAcquir Immune Defic Syndr;80(2)
dc.subjectcryptococcal meningitis,en_US
dc.subjectcryptococcal antigenemia,en_US
dc.subjectHIV, fluconazole,en_US
dc.subjectmortality,en_US
dc.subjectsub-Saharan Africaen_US
dc.titleLaboratory-reflex cryptococcal antigen screening is associated with a survival benefit in Tanzaniaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Diana Faini.pdf
Size:
487.39 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description: